Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Latigo Biotherapeutics Appoints Neil Singla, M.D. As Chief Medical Officer

PRIVATEAug 19, 2024•almost 2 years ago

Position

Chief Medical Officer

Company

Latigo Biotherapeutics

Neil Singla

Thousand OaksBiotechnology

Description

Latigo Biotherapeutics Inc. announced positive Phase 1 results for LTG-001, its lead potential best-in-class non-opioid pain medicine candidate. The company also appointed world-renowned analgesic scientist Neil Singla, M.D., as chief medical officer.

Company Information

Company

Latigo Biotherapeutics

Location

Thousand Oaks, California, United States

About

Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the fundamental mechanism of pain transduction. The company’s proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machine learning, structure-based, and knowledge-based design techniques to optimize potency and selectivity. The company is backed by top-tier investors, including Westlake Village BioPartners, 5AM Ventures, Foresite Capital, and Corner Ventures.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Latigo Biotherapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months